Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Hanne Melgaard Nielsen"'
Autor:
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj-Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Knoop, Iben Kümler
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/b7ed109fa6b54fd1a10b6903857bb409
Autor:
Mathilde Louise Gehrchen, Tobias Berg, Rasmus Garly, Maj-Britt Jensen, Saskia Eßer-Naumann, Jeanette Dupont Rønlev, Hanne Melgaard Nielsen, Ann Knoop, Iben Kümler
Publikováno v:
BJC Reports, Vol 2, Iss 1, Pp 1-8 (2024)
Abstract Background Initial treatment for advanced ER-positive/HER2-negative breast cancer involves a CDK 4/6 inhibitor (CDK 4/6i). Recent overall survival (OS) analyses led the Danish Medical Council to exclude palbociclib as preferred option. This
Externí odkaz:
https://doaj.org/article/d2612f5ad8f047cebfc8ffc4d7d6b96a
Autor:
Alan Celik, Tobias Berg, Maj-Britt Jensen, Erik Jakobsen, Hanne Melgaard Nielsen, Iben Kümler, Vesna Glavicic, Jeanette Dupont Jensen, Ann Knoop
Publikováno v:
Breast Cancer: Basic and Clinical Research, Vol 17 (2023)
Background: Metastatic triple-negative breast cancer (mTNBC) is an aggressive subtype of breast cancer with poor survival. Currently, the literature lacks comprehensive real-world evidence on locally recurrent and mTNBC patients. To validate the opti
Externí odkaz:
https://doaj.org/article/8667cce3158e4750a5ea7c2781852e06
Autor:
Marie Overgaard, Hanne Melgaard Nielsen, Trine Tramm, Inger Højris, Trine Lønbo Grantzau, Jan Alsner, Birgitte Vrou Offersen, Jens Overgaard
Publikováno v:
Overgaard, M, Nielsen, H M, Tramm, T, Højris, I, Grantzau, T L, Alsner, J, Offersen, B V, Overgaard, J & DBCG Radiotherapy Group 2022, ' Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial ', Radiotherapy and Oncology, vol. 170, pp. 4-13 . https://doi.org/10.1016/j.radonc.2022.03.008
Background: Between 1982 and 1990 the Danish Breast Cancer Cooperative Group (DBCG) conducted a randomized trial in high-risk pre- and postmenopausal (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3288360f89eb84b168dfb2435fdc1ac
https://doi.org/10.1016/j.radonc.2022.03.008
https://doi.org/10.1016/j.radonc.2022.03.008
Autor:
M. H. Kristensen, Anders Winther Mølby Nielsen, Hanne Melgaard Nielsen, Marie Lundorff, Jan Alsner, Birgitte Vrou Offersen, Robert Zachariae
Publikováno v:
Nielsen, A W M, Lundorff, M, Nielsen, H M, Alsner, J, Vrou Offersen, B, Kristensen, M H & Zachariae, R 2021, ' Symptom trajectories in breast cancer survivors: growth mixture analysis of patient-reported pain, fatigue, insomnia, breast and arm symptoms ', Acta Oncologica, vol. 60, no. 12, pp. 1659-1667 . https://doi.org/10.1080/0284186X.2021.1981550
BACKGROUND: Variations in symptom development among breast cancer (BC) survivors are understudied. We examined: (Q1) Symptom trajectories of pain, fatigue, insomnia, breast, and arm symptoms in BC survivors, (Q2) possible patterns or cluster-like ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c434f376155fb501ac8c632d5f353984
https://pure.au.dk/portal/da/publications/symptom-trajectories-in-breast-cancer-survivors-growth-mixture-analysis-of-patientreported-pain-fatigue-insomnia-breast-and-arm-symptoms(2041afa5-69fa-46c0-8c84-e68b78b0fa62).html
https://pure.au.dk/portal/da/publications/symptom-trajectories-in-breast-cancer-survivors-growth-mixture-analysis-of-patientreported-pain-fatigue-insomnia-breast-and-arm-symptoms(2041afa5-69fa-46c0-8c84-e68b78b0fa62).html
Autor:
Anders Winther Mølby Nielsen, Hanne Melgaard Nielsen, Robert Zachariae, Jan Alsner, M. H. Kristensen, Birgitte Vrou Offersen
Publikováno v:
Nielsen, A W M, Kristensen, M H, Offersen, B V, Alsner, J, Zachariae, R & Nielsen, H M 2021, ' Patient-reported outcomes in postmenopausal breast cancer survivors–comparisons with normative data ', Acta Oncologica, vol. 60, no. 1, pp. 78-86 . https://doi.org/10.1080/0284186X.2020.1834143
Background: Survival rates for breast cancer (BC) are increasing, leading to growing interest in treatment-related late-effects. The aim of the present study was to explore late effects using Patient-Reported Outcome Measures in postmenopausal BC sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bde3a1ef23c2c8ce190df6f313236d7
https://pure.au.dk/portal/da/publications/patientreported-outcomes-in-postmenopausal-breast-cancer-survivorscomparisons-with-normative-data(590588d0-6ff2-43a3-9dca-f860db8347d1).html
https://pure.au.dk/portal/da/publications/patientreported-outcomes-in-postmenopausal-breast-cancer-survivorscomparisons-with-normative-data(590588d0-6ff2-43a3-9dca-f860db8347d1).html
Autor:
Jens Overgaard, M.H. Nielsen, Unn miriam Kasti, Mechthild Krause, Andreas Schreiber, Birgitte Vrou Offersen, Ingvil Mjaaland, Lars Stenbygaard, Jan Alsner, Erik Jakobsen, Hanne Melgaard Nielsen
Publikováno v:
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Krause, M, Stenbygaard, L, Mjaaland, I, Schreiber, A, Kasti, U M, Overgaard, J & Danish Breast Cancer Group Radiation Therapy Committee 2020, ' Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial : The DBCG HYPO Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 31, pp. 3615-3625 . https://doi.org/10.1200/JCO.20.01363
Journal of Clinical Oncology 38(2020)31, 3615
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Krause, M, Stenbygaard, L, Mjaaland, I, Schreiber, A, Kasti, U M, Overgaard, J & Danish Breast Cancer Group Radiation Therapy Committee 2020, ' Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial : The DBCG HYPO Trial ', Journal of Clinical Oncology, vol. 38, no. 31, pp. 3615-3625 . https://doi.org/10.1200/JCO.20.01363
Journal of Clinical Oncology 38(2020)31, 3615
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Krause, M, Stenbygaard, L, Mjaaland, I, Schreiber, A, Kasti, U M, Overgaard, J & Danish Breast Cancer Group Radiation Therapy Committee 2020, ' Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial : The DBCG HYPO Trial ', Journal of Clinical Oncology, vol. 38, no. 31, pp. 3615-3625 . https://doi.org/10.1200/JCO.20.01363
PURPOSE Given the poor results using hypofractionated radiotherapy for early breast cancer, a dose of 50 Gy in 25 fractions (fr) has been the standard regimen used by the Danish Breast Cancer Group (DBCG) since 1982. Results from more recent trials h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd0ab8429e8d52813445896f545e7193
https://portal.findresearcher.sdu.dk/da/publications/2c9d0b27-18b1-43c9-98e4-257a87e3c2d9
https://portal.findresearcher.sdu.dk/da/publications/2c9d0b27-18b1-43c9-98e4-257a87e3c2d9
Autor:
Anders Winther Mølby Nielsen, Birgitte Vrou Offersen, M. H. Kristensen, Hanne Melgaard Nielsen, Robert Zachariae, Jan Alsner
Publikováno v:
Nielsen, A W M, Kristensen, M H, Offersen, B V, Alsner, J, Zachariae, R & Nielsen, H M 2020, ' Patient-reported outcome measures used for reporting late effects in postmenopausal breast cancer survivors and compared to general symptoms in a Danish female age matched population ', pp. S90 . https://doi.org/10.1016/S0959-8049(20)30776-0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da09c70fafc13f13925bbf6f949aacab
https://pure.au.dk/portal/da/publications/patientreported-outcome-measures-used-for-reporting-late-effects-in-postmenopausal-breast-cancer-survivors-and-compared-to-general-symptoms-in-a-danish-female-age-matched-population(39e7fe69-f297-4506-86e3-9105e1dafa55).html
https://pure.au.dk/portal/da/publications/patientreported-outcome-measures-used-for-reporting-late-effects-in-postmenopausal-breast-cancer-survivors-and-compared-to-general-symptoms-in-a-danish-female-age-matched-population(39e7fe69-f297-4506-86e3-9105e1dafa55).html
Autor:
Maj-Britt Jensen, M.S. Thomsen, B. Offersen, M.H. Nielsen, Ingelise Jensen, Hanne Melgaard Nielsen, Ebbe Laugaard Lorenzen, Anders N. Pedersen, Mirjana Josipovic, Lars Stenbygaard, E. H. Jacobsen, E.S. Yates, Martin Berg, Jan Alsner, Jens Overgaard
Publikováno v:
Radiotherapy and Oncology. 161:S247
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57d14c6da25fefb9247e8a8d57a646b5
https://doi.org/10.1016/s0167-8140(21)06867-5
https://doi.org/10.1016/s0167-8140(21)06867-5
Autor:
Søren Cold, Marianne Ewertz, Hanne Melgaard Nielsen, Julia Kenholm, Dorte Carlsen, Malgorzata K Tuxen, Ann Knoop, Eva Balslev, Troels Bechmann, Erik Jakobsen, Hella Danø, Michael Andersson, Dorte Nielsen, Inger Højris, Henning T. Mouridsen, Bent Ejlertsen, Else Maae, Peter Michael Vestlev, Maj-Britt Jensen
Publikováno v:
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Ejlertsen, B, Tuxen, M K, Jakobsen, E H, Jensen, M-B, Knoop, A S, Højris, I, Ewertz, M, Balslev, E, Danø, H, Vestlev, P M, Kenholm, J, Nielsen, D L, Bechmann, T, Andersson, M, Cold, S, Nielsen, H M, Maae, E, Carlsen, D & Mouridsen, H T 2017, ' Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer : DBCG 07-READ, an Open-Label, Phase III, Randomized Trial ', Journal of Clinical Oncology, vol. 35, no. 23, pp. 2639-2646 . https://doi.org/10.1200/JCO.2017.72.3494
Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a non-anthracycline-based regimen in TOP2A-normal patients. Patients and Methods In this multicenter, open-lab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d31fe2d3f63dba4f1402d624553e76
https://doi.org/10.1200/jco.2017.72.3494
https://doi.org/10.1200/jco.2017.72.3494